Please login to the form below

Not currently logged in
Email:
Password:

CEVEC and Catalent partner on cell lines

CEVEC Pharmaceuticals and Catalent Pharma Solutions have launched a joint commercial cell line development service for pharma and biotech customers worldwide

CEVEC Pharmaceuticals and Catalent Pharma Solutions have launched a joint commercial cell line development service for pharma and biotech customers worldwide. 

The offering combines the benefits of CEVEC's human cell line, CAP-Technology, with Catalent's unique GPEx (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.


Wolfgang Kintzel, managing director of CEVEC, said: "The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line."

16th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics